Megan Lynch/LinkedIn
Jun 16, 2026, 16:17
Megan Lynch: Thrilled to Join AstraZeneca
Megan Lynch, Global Product Leader, Cell Therapy Enterprise at AstraZeneca, shared a post on LinkedIn:
“I’m thrilled to share that I’m joining AstraZeneca as a Global Product Leader, Cell Therapy Enterprise.
Cell therapy is transforming how we treat patients across hem/onc, autoimmune, and rare disease.
Getting innovative medicines to patients and providers has always been my north star and I can’t wait to dig in.
Thank you to Margie Li, Margaret DiGuardo, Carsten Linnemann, Craig Maxwell, and Eva Piqué for your partnership throughout this process — I’m looking forward to what we’ll build together.
Here’s to what’s next.”
Stay updated with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering